Abstract:From the 33,000 men in the U.S. who die from prostate cancer each year, the majority of these patients exhibit metastatic disease with bone being the most common site of metastasis. Prostate cancer bone metastases are commonly blastic, exhibiting new growth of unhealthy sclerotic bone, which can cause painful skeletal related events. Patient's current care entails androgen deprivation therapy, anti-resorptive agents, radiation, and chemotherapy to help control the spread of the cancer but little intervention is available to treat blastic bone disease. The transforming growth factor beta (TGFβ) and bone morphogenetic protein (BMP) pathways are known to regulate bone growth and resorption of destructive lytic bone lesions, yet the role of TGFβ/BMP signaling in prostate cancer blastic vs lytic bone lesions are not fully understood. We hypothesized that to target the BMP/TGFβ pathway, a useful biomarker of bone lytic or blastic pathology would have superior response. We show distinct BMP vs. TGFβ signaling in clinical samples of human prostate cancer bone metastases with either lytic or blastic pathologies. BMPs exhibit distinct effects on bone homeostasis, so to examine the effect of BMP inhibition on healthy bone, we treated mice with the BMP receptor small molecule antagonist DMH1 and saw a modest temporary improvement in bone health, with increased trabecular bone. We next sought to use the BMP inhibitor DMH1 to treat bone metastasis engraftment seeded by a caudal artery injection of the lytic human prostate cell line PC3 in immunodeficient mice. The colonization by PC3 cells to the bone were restricted with DMH1 treatment and bone health was importantly preserved. We next proceeded to test BMP inhibition in an injury model of established bone metastasis via intratibial injection of the MYC-CaP mouse prostate cell line into FVBN syngeneic mice. DMH1 treated mice had a modest decrease in trabecular bone and reduced lymphocytes in circulation without affecting tumor growth. Taken together we show unique responses to BMP inhibition in metastatic prostate cancer in the bone. These studies suggest that profiling bone lesions in metastatic prostate cancer can help identify therapeutic targets that not only treat the metastatic tumor but also address the need to better treat the distinct tumor induced bone disease.

BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

BMP9 Inhibits Proliferation and Metastasis of HER2-positive SK-BR-3 Breast Cancer Cells Through ERK1/2 and PI3K/AKT Pathways.

Μolecular Impact of Bone Morphogenetic Proteinï¿½7, on Lung Cancer Cells and Its Clinical Significance

BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β 3 expression

BMP-7 functions as a novel hormone to facilitate liver regeneration.

Endogenous Bone Morphogenetic Protein-7 Controls the Motility of Prostate Cancer Cells Through Regulation of Bone Morphogenetic Protein Antagonists

Biological Effects Of Bmp7 On Small-Cell Lung Cancer Cells And Its Bone Metastasis

Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease

Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells.

Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases Through A Dual Mechanism

BMP7 Expression in Esophageal Squamous Cell Carcinoma and Its Potential Role in Modulating Metastasis.

HGF/SF Up-Regulates the Expression of Bone Morphogenetic Protein 7 in Prostate Cancer Cells.

Bone Morphogenetic Proteins and Their Receptor Signaling in Prostate Cancer.

Constitutive Activation of Activin Receptor-like Kinase 2 in Human Breast Cancer Cells inhibits Metastatic Progression and Osteolytic Bone Lesions

Function of BMP7 in the Genesis and Development of Colorectal Cancer

Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway.

BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells

Effects of ALK1Fc Treatment on Prostate Cancer Cells Interacting with Bone and Bone Cells in Bone Metastasis Models.